Excellence in Dermatology™
Excellence in Dermatologic Surgery™
Excellence in Medical Dermatology™
Excellence in Dermatopathology™

F032 - Field Cancer and Multiple SCC: Molecular Insights and Clinical Management

Friday, February 16; 3:30 PM - 5:30 PM

Learning Objectives

Following this course, the attendee should be able to:

  • Identify patients at risk for multiple SCC development.
  • Recognize the contribution of ultraviolet light and somatic mutation to SCC development within a field of actinic damage.
  • Select and prescribe appropriate field treatment for patients with multiple lesions.

Description

Development of multiple SCCs within areas of actinic damage is common and is best described by the field cancerization paradigm. This session, designed for general dermatologists and dermatologic surgeons, will discuss how ultraviolet light and acquired genetic mutations promote multiple SCC development within a damaged field of skin. Prevention, topical treatments, photodynamic therapy, and systemic treatments for field cancerization will be reviewed, along with the evidence to support their use. Participants will learn how to select the optimal field treatment strategy for individual patients, including combination treatment and management of high-risk populations such as organ transplant recipients.

Disclosures

  • Carucci, John A., MD, PhD: GlaxoSmithKline – I(Grants/Research Funding); Novartis Pharmaceuticals Corp. – I(NC); Pfizer Inc. – I(NC); Regeneron – I(Grants/Research Funding);
  • Christensen, Sean, MD, PhD: Novartis – I(Grants/Research Funding); PellePharm, Inc. – I(Grants/Research Funding);
  • Colegio, Oscar, MD, PhD: no financial relationships exist with commercial interests.
  • Goldenberg, Gary, MD: AbbVie – SP(H); Allergan, Inc – C(H); Anacor Pharmaceuticals, Inc. – C(H); Bayer – SP(H); Bayer Pharmaceuticals – C(H); Castle Biosciences – SP(H); Celgene Corporation – C(H), SP(H); Dermira – A(H); Eclipse Medical – C(H); Eli Lilly and Company – C(Fees), SP(H); Galderma USA – SP(H); Genentech, Inc. – C(H); Janssen Pharmaceuticals, Inc – C(H); Leo Pharma A/S – I(Grants/Research Funding); LEO Pharma, US – C(H), SP(H); MelaSciences – C(H); Novartis Pharmaceuticals Corp. – C(H), SP(H); Pfizer Inc. – C(H); Pharmaderm – A(H), I(Grants/Research Funding), SP(H); Ranbaxy Laboratories Limited – C(H); Stiefel a GSK company – C(H), I(Grants/Research Funding); Taro Pharm – C(Fees); Teva Pharmaceuticals USA – C(Fees); Valeant Pharmaceuticals North America LLC – C(H), I(Grants/Research Funding), SP(H); Xoft – C(H);
  • Willey, Andrea, MD: no financial relationships exist with commercial interests.
Schedule
Friday, February 16
3:30 PM
Dr. Christensen / Intro to Field Cancer
3:50 PM
Dr. Goldenberg / Topical Field Therapy
4:10 PM
Dr. Willey / Photodynamic Field Therapy
4:30 PM
Dr. Carucci / Systemic and Combination Field Therapy
4:50 PM
Dr. Colegio / Field Cancer in Transplant Recipients
5:10 PM
Dr. Christensen / Summary, Case Discussion and Questions
Event Details
  • Date
    Friday, February 16
  • Time
    3:30 PM - 5:30 PM
  • Location
    Room 25B
  • CME Credits
    2.00
  • Type
Directors/Co-Directors
  • Sean Christensen, MD, PhD, FAAD - Handout
Speakers
  • Andrea Willey, MD, FAAD
  • Gary Goldenberg, MD, FAAD - Handout
  • John A. Carucci, MD, PhD, FAAD
  • Oscar Colegio, MD, PhD, FAAD